Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Acq. announced
Director departure
CC transcript
|
|
ACHIEVE LIFE SCIENCES, INC. (ACHV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 — Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights • Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association • Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-..." |
|
| 06/09/2023 |
4
| HIMES VAUGHN B (Director) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Granted 31,500 options to buy
@ $6, valued at
$189k
|
|
| 06/09/2023 |
4
| Martell Bridget A (Director) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Granted 31,500 options to buy
@ $6, valued at
$189k
|
|
| 06/09/2023 |
4
| Sellig Thomas (Director) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Granted 23,250 options to buy
@ $5.97, valued at
$138.8k
|
|
| 06/09/2023 |
4
| Duty Stuart (Director) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Granted 23,250 options to buy
@ $5.97, valued at
$138.8k
|
|
| 06/09/2023 |
4
| KING THOMAS BRAXTON (Director) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Granted 23,250 options to buy
@ $5.97, valued at
$138.8k
|
|
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/02/2023 |
SC 13G/A
| Contrarian Alpha, LP reports a 9.7% stake in Achieve Life Sciences, Inc. |
| 06/01/2023 |
4
| Bencich John (CEO) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Bought 5,000 shares
@ $5.5, valued at
$27.5k
|
|
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
". IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 31",
"Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia, May 25, 2023 -- Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering. The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the proceeds from the o..." |
|
| 05/23/2023 |
8-K
| Investor presentation|
Docs:
|
"References 1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014. 3 Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483. 4Park Lee E, Ren C, Cooper M, Cornelius M, Jamal A, Cullen KA. Tobacco Product Use Among Middle and High School Students – United States, 2022. Morbidity and Mortality Weekly Report, 2022; 71:45.",
"2 3 4 5 6 7 8 9 10 11 12 16 20 24" |
|
| 05/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT THIS 2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT is dated as of the Effective Date among SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY , in its capacity as administrative agent and collateral agent , SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY, as a lender, SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership , as a lender, INNOVATION CREDIT FUND VIII-A, L.P., a Delaware limited partnership , as a lender , and and the borrower listed on Schedule I hereto . WHEREAS, each of the Borrower, Innovation and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company , as lender and as agent thereunder, have heretofore entered into that certain 2021 Contingent Convertible Debt...",
"RECITALS WHEREAS, the Company and the Lenders are parties to that certain 2023 Contingent Convertible Debt Agreement of even date herewith, as amended or otherwise modified or supplemented and in effect from time to time ; and WHEREAS, Company and the Lenders desire to provide for certain rights of registration under the Securities Act of 1933, as amended with respect to the Conversion Shares . NOW, THEREFORE, in consideration of the promises, covenants and conditions set forth herein, the parties hereto hereby agree as follows: 1. Registration Rights. 1.1 Definitions. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Loan Agreement. As used in this Agreement, the following terms shall have the meanings set forth below: “Affiliate” ..." |
|
| 05/16/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development 5,534 4,388 General and administrative 3,044 2,838 Total operating expenses 8,578 7,226 Loss from operations Other income Net loss $ $ Basic and diluted net loss per share $ $ Weighted average number of basic and diluted common shares 17,917,769 9,458,745 Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets: Cash and cash equivalents $ 16,514 $ 24,771 Prepaid expenses and other current assets 1,710 2,559 Other assets and restricted cash 68 123 Right-of-use assets 109 66 License agreement 1,363 1,418 Goodwill 1,034 1,034 Total assets $ 20,798 $ 29,971 Liabilities and stockholders' equity: Accounts payable and accrued liabilities $ 3,872 $ 5,470 Current portion..." |
|
| 05/01/2023 |
4
| Wan Jerry (Principal Accounting Officer) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Paid exercise price by delivering 669 shares
@ $8.29, valued at
$5.5k
Exercised 1,250 options to buy
@ $0 |
|
| 05/01/2023 |
4
| JACOBS CINDY (President & CMO) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Paid exercise price by delivering 609 shares
@ $8.29, valued at
$5k
Exercised 2,500 options to buy
@ $0 |
|
| 05/01/2023 |
4
| Bencich John (CEO) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Paid exercise price by delivering 1,827 shares
@ $8.29, valued at
$15.1k
Exercised 7,500 options to buy
@ $0 |
|
| 05/01/2023 |
4
| Stewart Richard Alistair (Executive Chairman) has filed a Form 4 on ACHIEVE LIFE SCIENCES, INC.|
Txns:
| Paid exercise price by delivering 2,250 shares
@ $8.29, valued at
$18.7k
Exercised 5,000 options to buy
@ $0 |
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/25/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/23/2023 |
SC 13D/A
| DIALECTIC CAPITAL MANAGEMENT, LP reports a 19.8% stake in ACHIEVE LIFE SCIENCES, INC. |
|
|
|